Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15 USD | -1.67% | +2.20% | 0.00% |
Apr. 25 | Nasdaq's revenue beats on strong demand for fintech products | RE |
Mar. 26 | Kyverna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 3.75M | Sales 2025 * | 5M | Capitalization | 658M |
---|---|---|---|---|---|
Net income 2024 * | -130M | Net income 2025 * | -199M | EV / Sales 2024 * | 123 x |
Net cash position 2024 * | 197M | Net cash position 2025 * | 142M | EV / Sales 2025 * | 103 x |
P/E ratio 2024 * |
-4.8
x | P/E ratio 2025 * |
-3.85
x | Employees | 96 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.27% |
1 day | -1.67% | ||
1 week | +2.20% | ||
Current month | +1.32% | ||
1 month | -34.11% |
Managers | Title | Age | Since |
---|---|---|---|
Peter Maag
CEO | Chief Executive Officer | 56 | 22-10-12 |
Ryan Jones
DFI | Director of Finance/CFO | 36 | 17-12-31 |
Dominic Borie
CTO | Chief Tech/Sci/R&D Officer | 61 | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Beth Seidenberg
BRD | Director/Board Member | 67 | 18-08-31 |
Ian Clark
CHM | Chairman | 62 | 21-09-14 |
Dan Spiegelman
BRD | Director/Board Member | 65 | 21-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 15.3 | +0.33% | 2 046 |
24-05-03 | 15.25 | +1.46% | 459,649 |
24-05-02 | 15.03 | -9.51% | 538,183 |
24-05-01 | 16.61 | +9.71% | 731,696 |
24-04-30 | 15.14 | +0.87% | 374,472 |
Delayed Quote Nasdaq, May 06, 2024 at 09:46 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 658M | |
+24.05% | 47.9B | |
+46.40% | 41.42B | |
-2.50% | 40.7B | |
-6.20% | 28.92B | |
+9.51% | 25.55B | |
-20.93% | 19.27B | |
-0.66% | 12.15B | |
+29.48% | 12.14B | |
-0.78% | 11.99B |
- Stock Market
- Equities
- KYTX Stock